

Francesca Battaglin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7118338/francesca-battaglin-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104
papers

1,144
citations

17
h-index

32
g-index

130
ext. papers

1,596
ext. citations

4.1
avg, IF

4.28
L-index

#	Paper	IF	Citations
104	Hippo pathway signaling associated with immune cell trafficking in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 156-156	2.2	
103	The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 143-143	2.2	
102	The role of genetic variants involved with ferroptosis regulator genes in predicting outcomes in patients (pts) with RAS-mutant metastatic colorectal cancer (mCRC): Data from MAVERICC and TRIBE trials.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 197-197	2.2	
101	LRP1B and GRM3 expression in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 177-177	2.2	
100	Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 246-246	2.2	
99	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2021 ,	9.2	2
98	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021 , 5, 95	9.8	1
97	RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1153-1160	6.1	0
96	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3234-3242	12.9	5
95	Clocking cancer: the circadian clock as a target in cancer therapy. <i>Oncogene</i> , 2021 , 40, 3187-3200	9.2	7
94	Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3041-3041	2.2	0
93	The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3581-3581	2.2	
92	Association of high gene expression levels of ARF6 with the immune microenvironment and prediction of poor outcomes.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3092-3092	2.2	0
91	Molecular Determinants of Gastrointestinal Cancers. <i>Advances in Oncology</i> , 2021 , 1, 311-325		
90	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021 , 11, 12191	4.9	0
89	Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 150, 133-142	7.5	1
88	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021 , 40, 4894-4905	9.2	2

87	Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 118-118	2.2	
86	Molecular characterization of pancreatic cancers as seen in the SLUG gene revealing cancer progression.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 433-433	2.2	1
85	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies 2020 , 8,		15
84	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020 , 12,	6.6	7
83	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020 , 5, e000682	6	34
82	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020 , 131, 89-97	7.5	3
81	The landscape of DNA damage response (DDR) pathway in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4064-4064	2.2	2
80	Comprehensive molecular profiling of IDH1/2 mutant biliary cancers (BC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 479-479	2.2	6
79	Molecular characterization of appendiceal goblet cell carcinoid.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 231-231	2.2	
78	Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 245-245	2.2	0
77	Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 187-187	2.2	
76	Comprehensive molecular analysis of microsatellite-stable (MSS) tumors with high mutational burden in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3631-3631	2.2	
75	Somatic alterations of NF1 in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4066-4066	2.2	
74	Molecular correlates of PD-L1 expression in patients (pts) with gastroesophageal (GE) cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4558-4558	2.2	
73	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 404-413	5.7	13
72	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 140, 119-129	7.5	13
71	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2634-2640	6.1	4
70	Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. <i>ESMO Open</i> , 2020 , 5, e000942	6	11

69	Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 2020 , 8,		4
68	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020 , 26, 5943-5951	12.9	17
67	Partition: a surjective mapping approach for dimensionality reduction. <i>Bioinformatics</i> , 2020 , 36, 676-681	7.2	2
66	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3096-3103	12.9	30
65	Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019 , 111, 138-147	7.5	3
64	AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019 , 145, 2082-2090	7.5	0
63	Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019 , 45, 139-154	8.8	19
62	The impact of panitumumab treatment on survival and quality of life in patients with wild-type metastatic colorectal cancer. <i>Cancer Management and Research</i> , 2019 , 11, 5911-5924	3.6	15
61	Comprehensive molecular characterization of brain metastases (BM) from colorectal cancer (CRC). <i>Annals of Oncology</i> , 2019 , 30, v764	10.3	2
60	Molecular insight of regorafenib treatment for colorectal cancer. <i>Cancer Treatment Reviews</i> , 2019 , 81, 101912	14.4	44
59	BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3145-3145	2.2	2
58	Molecular landscape of colorectal cancers harboring R-spondin fusions.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3588-3588	2.2	3
57	Gene mutations of SWI/SNF complex and molecular profile in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3600-3600	2.2	1
56	Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4085-4085	2.2	8
55	Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4133-4133	2.2	8
54	Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 606-606	2.2	3
53	Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 594-594	2.2	
52	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 564-564	2.2	

51	Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 566-566	2.2	
50	Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 558-558	2.2	
49	Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 63-63	2.2	
48	Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3545-3545 ^{2,2}	2.2	
47	Gene expression and genetic variants in Parkinson's disease (PD) genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3595-3595	2.2	0
46	Molecular differences between lymph nodes (LNs) and distant metastases (mets) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3130-3130	2.2	
45	Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3048-3048	2.2	0
44	Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2633-2633	2.2	
43	Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e8-e19	3.8	9
42	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019 , 42, 211-233	5.1	40
41	B cell and B cell-related pathways for novel cancer treatments. <i>Cancer Treatment Reviews</i> , 2019 , 73, 10-19	14.4	59
40	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018 , 66, 15-22	14.4	74
39	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 251-266	3.5	29
38	Biomarker-driven and molecular targeted therapies for colorectal cancers. <i>Seminars in Oncology</i> , 2018 , 45, 124-132	5.5	7
37	Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. <i>Acta Oncologica</i> , 2018 , 57, 412-419	3.2	0
36	Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. <i>Cancer Cell International</i> , 2018 , 18, 99	6.4	34
35	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 98	4.8	6
34	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018 , 13, e0193640	3.7	3

33	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12106-12106	2.2	2
32	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3576-3576	2.2	1
31	Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 645-645	2.2	1
30	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. <i>Clinical Advances in Hematology and Oncology</i> , 2018 , 16, 735-745	0.6	40
29	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018 , 4,	3.8	2
28	Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 662-662	2.2	
27	Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12098-12098	2.2	
26	Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3611-3611	2.2	
25	Genetic variations in the α M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12107-12107	2.2	
24	The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15578-e15578	2.2	
23	Management of Advanced Small Bowel Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 69	5.4	8
22	Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. <i>Gastric Cancer</i> , 2017 , 20, 825-833	7.6	24
21	Colorectal cancer: epigenetic alterations and their clinical implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 439-448	11.2	35
20	Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy. <i>Oncologist</i> , 2017 , 22, 1463-1469	5.7	17
19	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017 , 123, 4506-4514	6.4	14
18	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1297-1308	5.4	17
17	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2414-2422	12.9	111
16	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561	10.3	32

15	Angiogenesis inhibitor bevacizumab and symptomatic anal ulcers in metastatic colorectal cancer patients: A single center experience.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15042-e15042	2.2	
14	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 988-94	5.7	72
13	Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3540-3540	2.2	1
12	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3543-3543	2.2	9
11	Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 733-733	2.2	
10	Induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC): The phase II TRUST trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 673-673	2.2	
9	Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3627-TPS3627	2.2	
8	Genetic variants of Pin1 to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11589-11589	2.2	
7	Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3615-3615	2.2	
6	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2141-7	2.2	170
5	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 877-85	3.8	10
4	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015 , 117, 315-21	5.3	24
3	Are circulating tumor cells (CTCs) a feasible tool for predicting disease recurrence and survival in nonmetastatic (M0) colorectal cancer (CRC)?.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 650-650	2.2	
2	Using mutational load in next generation sequencing (NGS) to identify mismatch repair (MMR) deficiency in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3565-3565	2.2	
1	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3596-3596	2.2	4